

Table 2. Results from post hoc analysis of KEYNOTE-062 for all patients and for patients with MSI-H tumours, PD-L1 CPS ≥ 1 ²⁵

	Pembrolizumab	Pembrolizumab plus chemotherapy	Chemotherapy
Overall results			
Total patients (No.)	256	257	250
ORR % (95%CI)	14.8 (10.7-19.8)	48.6 (42.4-54.9)	37.2 (31.2-43.5)
CR %	3.5	7.4	5.6
PR %	11.3	41.2	31.6
SD %	27.0	28.8	41.6
PD %	41.0	7.4	8.4
Median PFS, months (95% CI)	2.0 (1.5-2.8)	6.9 (5.8-7.3)	6.4 (5.7-7.1)
Median OS, months (95% CI)	10.6 (7.7-13.8)	12.5 (10.8-13.9)	11.1 (9.2-12.8)
Estimated OS % (95% CI)			
12 months	47 (41-53)	53 (47-59)	46 (39-52)
24 months	27 (21-32)	24 (19-30)	19 (15-24)
Results for MSI-H tumours			
Total patients (No.)	14	17	19
ORR % (95%CI)	57.1 (28.9-82.3)	64.7 (38.3-85.8)	36.8 (16.3-61.6)
CR %	7.1	35.3	10.5
PR %	50.0	29.4	26.3
SD %	21.4	17.6	42.1
PD %	14.3	0	10.5
PFS	11.2 (1.5-NR)	NR (3.6-NR)	6.6 (4.4-8.3)
OS	NR (10.7-NR)	NR (3.6-NR)	8.5 (5.3-20.8)
Estimated OS % (95% CI)			
12 months	79 (47-92)	71 (43-87)	47 (24-67)
24 months	71 (41-88)	65 (39-82)	26 (10-57)
CI: confidence interval; CR: complete response; MSI-H: microsatellite instability high; NR: not reached; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression free survival; PR: partial response; SD: stable disease			